Navigation Links
Varian Medical Systems Schedules First Quarter FY2009 News Release and Conference Call
Date:12/10/2008

PALO ALTO, Calif., Dec. 10 /PRNewswire-FirstCall/ -- Varian Medical Systems (NYSE: VAR) announced today that it will report results for first quarter of fiscal year 2009 following the close of regular trading on Thursday, January 29, 2009. The news release will be followed by a teleconference available to all interested parties at 2:00 p.m. PT.

The Varian Medical Systems quarterly results can be accessed on January 29, 2009. The news release and information on the conference call webcast will be available on the company website at: www.varian.com/investor. Details on the conference call and replay follow:

    Teleconference:   Telephone from within the U.S.:
                      -- Dial 1-866-271-0675 and enter access code
                         46529406 prior to the call at
                         2:00 p.m. PT/5:00 p.m. ET.
                         Telephone from outside the U.S.:
                      -- Dial 1-617-213-8892 and enter access code
                         46529406 prior to the call at
                         2:00 p.m. PT/5:00 p.m. ET.
                      *Note: If the number of lines allocated to the
                      call is exhausted, the webcast or replay should be
                      utilized.

    Replay:           The teleconference will be rebroadcast until
                      8:00 p.m. ET, Friday, January 30, 2009 and can be
                      accessed by phone or Web link as follows:
                      -- Telephone from within the U.S.: Dial
                         1-888-286-8010 and enter access code 54317886.
                      -- Telephone from outside the U.S.: Dial
                         1-617-801-6888 and enter access code 54317886.
                      -- Internet: Click on the "Quarterly Conference Call"
                         icon on the company's investor relations website
                         at www.varian.com/investor
                      -- Web conferences will be archived on the company
                         website for a year.

For automatic "e-mail alerts" regarding Varian news and events investors can subscribe on the company website: http://varian.investorroom.com/index.php?s=58.

For additional information contact Anne Rambo at 650-424-5834 or anne.rambo@varian.com.

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 4,800 people who are located at manufacturing sites in North America and Europe and in its 60 sales and support offices around the world. For more information, visit http://www.varian.com/.

    FOR INFORMATION CONTACT:
    Spencer Sias, (650) 424-5782
    Vice President, Corporate Communications
    and Investor Relations
    spencer.sias@varian.com


'/>"/>
SOURCE Varian Medical Systems
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. NEW Line of Pushbutton Pill Cases Launched by Variant Products
2. Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto
3. Few Ontario women with invasive ovarian cancer referred for genetic testing of breast cancer genes
4. International study supports new standard of treatment for women with advanced ovarian cancer
5. Study unmasks how ovarian tumors evade immune system
6. Varian Medical Systems to Exhibit the Latest X-Ray Image Detectors, X-Ray Tubes, and Cancer Treatment Technologies at RSNA This Year
7. Ortho Biotech Announces NDA Submission for Trabectedin for the Treatment of Relapsed Ovarian Cancer
8. New platinum-phosphate compounds kill ovarian cancer cells
9. Protein compels ovarian cancer cells to cannibalize themselves
10. Top Indian Cancer Hospital to Introduce Advanced Radiosurgery Treatments With Novalis Tx from Varian Medical Systems and BrainLAB
11. Varian Medical Systems Schedules Fiscal Year End Review in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... ... Studies show evidence that carotenoids and antioxidants derived either from the diet or from ... how often do ophthalmologists and optometrists in Sweden recommend the use of nutritional supplements, ... symptoms of AMD? A study published recently in Dove Medical Press journal, ...
(Date:6/23/2017)... ... June 23, 2017 , ... Dr. Ran ... York, has recently begun offering three new minimally invasive procedures to patients who ... and reducing downtime, Dr. Rubinstein is excited to bring microneedling, microneedling facials, and ...
(Date:6/23/2017)... ... June 23, 2017 , ... Everybody has their own ... others prefer to read it, and some people don't like it at all. FindaTopDoc ... what they found: , Erotic literature can give readers a taste of their deepest, ...
(Date:6/23/2017)... Beverly Hills, CA (PRWEB) , ... June 23, 2017 , ... ... deep plane facelift . Dr. Talei has come up with a proprietary technique ... wrinkles—it releases and lifts tissues that have dropped. For all ages, patients can expect ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... Conference from Sept. 18 to 20. , The two-day conference is focused on ... the goal of improving patients’ lives and eliminating racial breast cancer-related disparities. The ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... , June 8, 2017  Less than a month ... more than 200,000 companies, including hospital networks, in over ... as one of the largest online extortion attempts ever ... healthcare market, it is imperative that providers understand where ... data from this — and many other very real ...
(Date:6/7/2017)... 2017  Novavax, Inc., (Nasdaq: NVAX ) today ... trials of its RSV F protein recombinant nanoparticle vaccine candidate ... been published in the journal Vaccine ... prior scientific conferences). The Company previously announced top line ... developing the RSV F Vaccine with the goal of protecting ...
(Date:6/3/2017)... , June 3, 2017  Eli Lilly and ... that results from the Phase 3 MONARCH 2 ... & 6 inhibitor, in combination with fulvestrant, significantly ... fulvestrant alone in women with hormone-receptor-positive (HR+), human ... cancer who have relapsed or progressed after endocrine ...
Breaking Medicine Technology: